The following message is provided in English first, and the Chinese version comes right after.

Investing.com (2026-06-10)

Prenetics raises 2026 IM8 revenue guidance on strong growth

NEW YORK - Prenetics Global Limited (NASDAQ:PRE) reported first-quarter revenue of $36.0 million and raised its full-year 2026 revenue guidance for its IM8 health brand to $190 million to $210 million, up from a previous range of $180 million to $200 million, according to a press release statement issued today.

The company's IM8 brand generated $33.8 million in revenue during the first quarter ended March 31, 2026, representing a 23.1% increase from $27.4 million in the fourth quarter of 2025 and nearly six times the $5.7 million recorded in the first quarter of 2025. The strong performance has driven Prenetics' market capitalization to $352 million, with shares returning 162%over the past year and trading at $20.93, near their 52-week high of $23.63. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate, placing it among companies on the most overvalued list.

IM8 monthly revenue reached $16.7 million in May 2026, up 19.3% from April's$14.0 million. The brand now ships to 43 countries, with over 60% of revenue generated outside the United States.

Prenetics projects second-quarter 2026 revenue of $46 million to $48 million, with IM8 contributing $44 million to $46 million, representing approximately 33% sequential quarterly growth for the brand.

The company reported a first-quarter loss of $23.1 million, driven primarily by non-cash items including a $9.8 million unrealized fair-value loss on digital assets and an $8.0 million fair-value loss on warrant liabilities. Adjusted EBITDA loss was $5.6 million. InvestingPro Tips indicate that analysts do not anticipate the company will be profitable this year, though they do expect continued sales growth. The platform offers 6 additional exclusive tips for PRE, along with comprehensive financial health scores and advanced metrics for deeper analysis.

IM8's gross margin improved to approximately 64% in the first quarter from60% in the fourth quarter of 2025. The brand delivered over 8.8 million servings during the quarter, up 28% from the prior quarter.

Prenetics divested its digital asset holdings after March 31, 2026, selling 510units for approximately $41.3 million at an average price of approximately $80,980 per unit. As of May 31, 2026, the company reported estimated cash balances of approximately $83.4 million. The company maintains a strong current ratio of 2.97, and notably holds more cash than debt on its balance sheet, providing financial flexibility as it scales IM8 operations.

The company plans to launch three new IM8 products in the fourth quarter of2026 in hydration, creatine, and kids' gummies categories. Prenetics appointed Brian J. Rosin as Chief Financial Officer of IM8.

In other recent news, Prenetics Global Limited reported preliminary first-quarter revenue of $36.0 million and raised its full-year 2026 revenue guidance for its IM8 supplement brand. The company increased its 2026 IM8revenue guidance to a range of $190 million to $210 million, reflecting growth from a previous range of $180 million to $200 million. IM8 generated $33.8million in revenue during the first quarter, marking a 23.1% increase from the fourth quarter of 2025. Additionally, Prenetics announced a multi-year partnership with Jay Shetty, who becomes a global ambassador for its IM8health brand and a shareholder in the company. This partnership marks Shetty as IM8's first global ambassador from outside professional sports.

Further developments include Prenetics appointing Hudson Leogrande, CEO of Comfrt, to its board of directors as an independent director. The company also named Brian J. Rosin as U.S. Chief Financial Officer for IM8, enhancing its finance leadership. In a strategic move, IM8 became the exclusive health supplements partner of Inter Miami CF, marking the first time the club has taken an equity stake in a brand partner.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Prenetics 上調 2026 年 IM8 健康品牌全年收入指引，強勁增長動能持續

紐約 —Prenetics Global Limited（納斯達克：PRE）今日發布新聞稿，公布第一季度總收入為 3,600 萬美元，並將旗下 IM8 健康品牌 2026 年全年收入指引上調至 1.9 億至 2.1 億美元，高於此前 1.8 億至 2 億美元的預測區間。

截至 2026 年 3 月 31 日的第一季度，IM8 品牌錄得收入 3,380 萬美元，較 2025 年第四季度的 2,740 萬美元增長 23.1%，並較 2025 年第一季度的 570 萬美元增長近六倍。受強勁業績推動，Prenetics 市值達到 3.52 億美元，股價過去一年累計回報率達 162%，目前報 20.93 美元，接近 52 週高位 23.63 美元。根據 InvestingPro 分析，該股目前相對於其公允價值估算呈現高估狀態，已被列入估值偏高股票名單。

M8 品牌 2026 年 5 月的月度收入達到 1,670 萬美元，較 4 月的 1,400 萬美元增長 19.3%。該品牌目前已向 43 個國家發貨，逾 60%的收入來自美國以外市場。

Prenetics 預計 2026 年第二季度總收入介於 4,600 萬至 4,800 萬美元之間，其中 IM8 貢獻 4,400 萬至 4,600 萬美元，意味著該品牌環比季度增長約 33%。

公司第一季度錄得虧損 2,310 萬美元，主要由非現金項目驅動，包括 980 萬美元的數字資產未實現公允價值損失，以及 800 萬美元的窩輪負債公允價值損失。調整後 EBITDA 虧損為 560 萬美元。InvestingPro 提示顯示，分析師預計公司今年仍難以實現盈利，但預期銷售額將持續增長。該平台另提供 6 項針對 PRE 的獨家分析提示，以及全面的財務健康評分與進階指標，供投資者深入研究。

IM8 品牌第一季度毛利率從 2025 年第四季度的 60%提升至約 64%。該品牌本季度共交付逾 880 萬份產品，較上一季度增長 28%。

Prenetics 已於 2026 年 3 月 31 日後完成數字資產的出售，共出售 510 個單位，總金額約 4,130 萬美元，平均每單位售價約 80,980 美元。截至 2026 年 5 月 31 日，公司估計現金餘額約為 8,340 萬美元。公司目前流動比率達

2.97，資產負債表上現金持有量顯著高於債務水平，為 IM8 業務的持續擴張提供充足的財務靈活性。

公司計劃於 2026 年第四季度推出三款 IM8 新產品，涵蓋補水、肌酸及兒童軟糖等品類。Prenetics 同時宣布任命 Brian J. Rosin 擔任 IM8 首席財務官。

此文章由人工智能協助翻譯。更多資訊，請參閱我們的使用條款。

Prenetics 上调 2026 财年 IM8 品牌收入指引，强劲增长势头持续

纽约 — 普诺明思全球有限公司（NASDAQ:PRE）发布新闻稿称，公司第一季度总收入为$3,600 万，并将旗下 IM8 健康品牌 2026 财年全年收入指引从此前的$1.8 亿至$2 亿上调至$1.9 亿至$2.1 亿。

截至 2026 年 3 月 31 日的第一季度，IM8 品牌实现收入$3,380 万，较 2025 年第四季度的$2,740 万环比增长 23.1%，较 2025 年第一季度的$570 万增长近六倍。受强劲业绩推动，普诺明思市值升至$3.52 亿，股价过去一年累计涨幅达 162%，目前报$20.93，接近 52 周高点$23.63。根据 InvestingPro 的分析，该股目前相对于其公允价值估算显得偏高，已被列入估值偏高股票名单。

IM8 品牌 2026 年 5 月月度收入达$1,670 万，较 4 月的$1,400 万环比增长 19.3%。目前该品牌已向 43 个国家发货，超过 60%的收入来自美国以外市场。

普诺明思预计 2026 年第二季度总收入为$4,600 万至$4,800 万，其中 IM8 品牌贡献$4,400 万至$4,600 万，意味着该品牌环比季度增长约 33%。

公司第一季度净亏损为$2,310 万，主要由非现金项目驱动，包括数字资产未实现公允价值损失$980 万及权证负债公允价值损失$800 万。调整后 EBITDA 亏损为$560 万。InvestingPro 提示显示，分析师预计公司今年仍难以实现盈利，但销售额有望持续增长。该平台还为 PRE 提供 6 条额外专属提示，以及全面的财务健康评分和深度分析指标。

IM8 品牌第一季度毛利率从 2025 年第四季度的 60%提升至约 64%。该品牌本季度共交付超过 880 万份产品，较上一季度增长 28%。

普诺明思已于2026年3月31日后出售全部数字资产，共出售510个单位，总价约$4,130万，平均每单位售价约$80,980。截至2026年5月31日，公司估计现金余额约为$8,340万。公司当前比率为2.97，资产负债表上现金持有量明显高于债务水平，为IM8业务规模扩张提供了充足的财务灵活性。

公司计划于2026年第四季度推出三款IM8新品，涵盖补水、肌酸及儿童软糖品类。普诺明思已任命Brian J. Rosin为IM8首席财务官。

本文由人工智能协助翻译。更多信息，请参见我们的使用条款。